Both bevacizumab (Avastin) and cetuximab (Epiduo) are effective drugs for the treatment of colorectal cancer, but both drugs are expensive, so most patients and their families would like to know which of these two targeted drugs is more effective. For metastatic colorectal cancer (stage IV) genetically tested K-RAS wild type, first-line chemotherapy combined with bevacizumab (Avastin) or cetuximab (Epiduo) is recommended to improve the efficacy and prolong survival compared with chemotherapy alone. The data reported in the CALGB80405 study, one of the most enigmatic studies at the 2014 American Society of Clinical Oncology (ASCO, very prestigious) annual meeting, is of great clinical relevance. CALGB80405 is the first multicenter, randomized, open-label, superiority III clinical study to compare head-to-head the efficacy of chemotherapy in combination with bevacizumab (Avastin) or cetuximab (Epiduo) in patients with KRAS wild-type metastatic colorectal cancer in primary care, with OS as the primary study endpoint, with 400 sites from the National Trials Network and 1,137 investigators participating in the The study. The design was scientific, rational, and convincing with a large sample size. The treatment regimen was oxaliplatin or irinotecan + calcium folinic acid + fluorouracil + bevacizumab or cetuximab. The chemotherapy regimen was chosen by the physician and the patient. The latest data from CALGB80405 showed that for patients with K-RAS wild-type metastatic colorectal cancer, first-line chemotherapy combined with bevacizumab (Avastin) or cetuximab (Epiduo), there was little difference between the two groups, with progression-free survival of 10.8 months and 10.4 months, respectively, and overall survival of 29 months and 29.9 months, respectively. The short answer is that both targeted agents have similar survival benefits and both can be used as first-line treatment options.